-
ICMag with help from Phlizon, Landrace Warden and The Vault is running a NEW contest for Christmas! You can check it here. Prizes are: full spectrum led light, seeds & forum premium access. Come join in!
Experience with psoriasis?
- Thread starter BakedBandit
- Start date
You can decarb in an insta pot
Hash Master 5000 - Dry Ice Method, Hash Oil Capsules, Everclear Tincture, RSO
=============================================================== Several Site rebuilds have broken the first 6 pages of Photo links so this will drop...
Legalcdn
Well-known member
VIDEO 3/4 way down the page for making a better version of RSO.
www.cannabishomesciences.com
It is really easy. I have done it a few times and i will be creating for soon.
Cannabis Home Sciences - RxCE Home Page
15 March 2023 R.x.C.E - Refined Cannabis Extract Oil, Faster, Cleaner and Cheaper. In the early 2000’s, Rick Simpson brought the healing quality of cannabis oil to the masses using simple extraction techniques. In the larger picture of extraction processes, this methodology is simple and oils are
www.cannabishomesciences.com
It is really easy. I have done it a few times and i will be creating for soon.
Canna salve works great for psoriasis. https://homesteadandchill.com/how-to-make-cannabis-salve/
I'm making it from kief. I have a way to infuse the oil already using kief. Will likely stick with that and just add a cup of coconut oil to dilute.
The infused oil for the capsules is 1/2 teaspoon per gram kief. Probably don't need lecithin. Could add bees wax, almond/olive oil and maybe essential oils to help.
The infused oil for the capsules is 1/2 teaspoon per gram kief. Probably don't need lecithin. Could add bees wax, almond/olive oil and maybe essential oils to help.
How much kief to coconut oil? - Chef's Resource
Contents How to Determine the Amount of Kief to Use When Making Coconut Oil When it comes to making cannabis-infused ... Read moreHow much kief to coconut oil?
www.chefsresource.com
How to Decarb Kief & Make Edibles
Learn how to decarb kief, the fine powdery substance found at the bottom of a grinder, and then make amazing edibles and topicals at home. You will also discover why kief can be more potent and get instructions on how to decarb your kief for best results.
emilykylenutrition.com
I find this thread very interesting and am looking into suggestions listed here. Though older, I appreciate the contributions here. I don’t have psoriasis but likely have some type of infectious agent that has plagued my health for a number of years now.
The below article is on Buchu . Fascinating read but is at the limits of my shade tree medical knowledge . I’m wondering interactions with other meds may be a factor here.
www.ncbi.nlm.nih.gov
The below article is on Buchu . Fascinating read but is at the limits of my shade tree medical knowledge . I’m wondering interactions with other meds may be a factor here.
Buchu (Agathosma betulina and A. crenulata): Rightfully Forgotten or Underutilized?
Today, the term buchu refers to the two species in commerce, Agathosma betulina (P.J.Bergius) Pillans and Agathosma crenulata (L.) Pillans (Rutaceae). Its traditional use in urinary tract infections and related ailments made it a popular remedy, specifically ...
www.ncbi.nlm.nih.gov
Yeah. I've got something going on. little fungus gnat larva biting me or something. they bite in the hair roots. CBD salve is amazing. I made some with a 1:1 thc/cbd strain. Also started this fendabendazole stuff 2 days ago. and it's working it's magic. along with that himalyan shiliajat stuff. along with oils. tea tree. rosemary. peppermint. and clove. the basic anti-pest oils. they make great sprays, too.
Growing a 1:1 thc/cbd strain was the best thing I've done lately. Health is improving a lot.
Growing a 1:1 thc/cbd strain was the best thing I've done lately. Health is improving a lot.
4.9.7.1 Inflammatory skin diseases (dermatitis, psoriasis, pruritus) ....................................................................... 128
drive.google.com
4.9.7.1 Inflammatory skin diseases (dermatitis, psoriasis, pruritus) ....................................................................... 128
information-health-care-professionals-cannabis-cannabinoids-eng.pdf
drive.google.com
4.9.7.1 Inflammatory skin diseases (dermatitis, psoriasis, pruritus) ....................................................................... 128
View attachment 19035418information-health-care-professionals-cannabis-cannabinoids-eng.pdf
PDF LINK ABOVE 266pg ebook
TABLE OF CONTENTS
Page
List of figures and tables .................................................................................................................................................................. 1
List of abbreviations ........................................................................................................................................................................ 2
Authorship and acknowledgements ................................................................................................................................................. 7
Overview of summary statements .................................................................................................................................................. 11
1.0 The Endocannabinoid System ............................................................................................................................................... 18
1.1 Cannabis ............................................................................................................................................................................ 22
1.1.1 Chemistry and composition ....................................................................................................................................... 22
1.1.2 Other constituents ..................................................................................................................................................... 22
1.1.3 Stability and storage .................................................................................................................................................. 22
2.0 Clinical Pharmacology........................................................................................................................................................... 24
2.1 Pharmacodynamics ............................................................................................................................................................ 24
2.2 Pharmacokinetics ............................................................................................................................................................... 29
2.2.1 Absorption ................................................................................................................................................................ 30
2.2.1.1 Smoked cannabis ........................................................................................................................................... 30
2.2.1.2 Vapourized cannabis ..................................................................................................................................... 30
2.2.1.3 Oral ............................................................................................................................................................... 31
2.2.1.4 Oro-mucosal and intranasal ........................................................................................................................... 33
2.2.1.5 Rectal ............................................................................................................................................................ 33
2.2.1.6 Topical .......................................................................................................................................................... 33
2.2.2 Distribution ............................................................................................................................................................... 34
2.2.3 Metabolism ............................................................................................................................................................... 34
2.2.3.1 Inhalation ...................................................................................................................................................... 35
2.2.3.2 Oral ............................................................................................................................................................... 35
2.2.4 Excretion ................................................................................................................................................................... 36
2.3 Pharmacokinetic-pharmacodynamic relationships ............................................................................................................. 36
2.4 Tolerance, dependence, and withdrawal symptoms ........................................................................................................... 39
2.5 Special populations ............................................................................................................................................................ 43
3.0 Dosing ..................................................................................................................................................................................... 46
3.1 Smoking ............................................................................................................................................................................. 48
3.2 Oral .................................................................................................................................................................................... 51
3.3 Oro-mucosal ...................................................................................................................................................................... 52
3.4 Vapourization..................................................................................................................................................................... 52
4.0 Potential Therapeutic Uses .................................................................................................................................................... 54
4.1 Palliative care ..................................................................................................................................................................... 56
4.2 Quality of life ..................................................................................................................................................................... 57
4.3 Chemotherapy-induced nausea and vomiting .................................................................................................................... 59
4.4 Wasting syndrome (cachexia, e.g., from tissue injury by infection or tumour) and loss of appetite (anorexia) in
AIDS and cancer patients, and anorexia nervosa ..................................................................................................................... 62
4.4.1 To stimulate appetite and produce weight gain in AIDS patients ............................................................................. 62
4.4.2 To stimulate appetite and produce weight gain in cancer patients ............................................................................ 63
4.4.3 Anorexia nervosa ...................................................................................................................................................... 64
4.5 Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury and disease ............................................................... 64
4.5.1 Multiple sclerosis ..................................................................................................................................................... 65
4.5.2 Amyotrophic lateral sclerosis .................................................................................................................................... 70
4.5.3 Spinal cord injury (or spinal cord disease) ................................................................................................................ 71
4.6 Epilepsy ............................................................................................................................................................................. 72
4.7 Pain .................................................................................................................................................................................... 78
4.7.1 Acute pain ................................................................................................................................................................. 80
4.7.1.1 Experimentally-induced acute pain ............................................................................................................... 81
4.7.1.2 Post-operative pain ........................................................................................................................................ 82
4.7.2 Chronic pain .............................................................................................................................................................. 82
vi
4.7.2.1 Experimentally-induced inflammatory and chronic neuropathic pain ........................................................... 82
4.7.2.2 Neuropathic pain and chronic non-cancer pain in humans ............................................................................ 82
4.7.2.3 Cancer pain ................................................................................................................................................... 91
4.7.2.4 “Opioid-sparing” effects and cannabinoid-opioid synergy ........................................................................... 93
4.7.2.5 Headache and migraine ................................................................................................................................ 98
4.8 Arthritides and musculoskeletal disorders ......................................................................................................................... 99
4.8.1 Osteoarthritis ............................................................................................................................................................. 99
4.8.2 Rheumatoid arthritis ................................................................................................................................................ 101
4.8.3 Fibromyalgia ........................................................................................................................................................... 102
4.8.4 Muscular pain ......................................................................................................................................................... 104
4.8.5 Osteoporosis ............................................................................................................................................................ 104
4.9 Other diseases and symptoms .......................................................................................................................................... 105
4.9.1 Movement disorders ............................................................................................................................................... 105
4.9.1.1 Dystonia ...................................................................................................................................................... 105
4.9.1.2 Huntington’s disease ................................................................................................................................... 107
4.9.1.3 Parkinson’s disease ..................................................................................................................................... 108
4.9.1.4 Tourette’s syndrome ................................................................................................................................... 109
4.9.1.5 Spinocerebellar ataxias .............................................................................................................................. 110
4.9.2 Glaucoma ............................................................................................................................................................... 110
4.9.3 Asthma ................................................................................................................................................................... 111
4.9.4 Hypertension .......................................................................................................................................................... 111
4.9.5 Stress and psychiatric disorders .............................................................................................................................. 111
4.9.5.1 Anxiety and depression .............................................................................................................................. 112
4.9.5.2 Sleep disorders ........................................................................................................................................... 114
4.9.5.3 Post-traumatic stress disorder ..................................................................................................................... 116
4.9.5.4 Alcohol and opioid withdrawal symptoms (drug withdrawal symptoms/drug substitution) ...................... 119
4.9.5.5 Schizophrenia and psychosis ...................................................................................................................... 121
4.9.6 Alzheimer’s disease and dementia .......................................................................................................................... 126
4.9.7 Inflammation .......................................................................................................................................................... 127
4.9.7.1 Inflammatory skin diseases (dermatitis, psoriasis, pruritus) ....................................................................... 128
4.9.8 Gastrointestinal system disorders (irritable bowel syndrome, inflammatory bowel disease,
hepatitis, pancreatitis, metabolic syndrome/obesity) .............................................................................................. 129
4.9.8.1 Irritable bowel syndrome ........................................................................................................................... 129
4.9.8.2 Inflammatory bowel diseases (Crohn’s disease, ulcerative colitis) ............................................................ 131
4.9.8.3 Diseases of the liver (hepatitis, fibrosis, steatosis, ischemia-reperfusion injury, hepatic
encephalopathy) ..................................................................................................................................................... 135
4.9.8.4 Metabolic syndrome, obesity, diabetes ...................................................................................................... 137
4.9.8.5 Diseases of the pancreas (diabetes, pancreatitis) ........................................................................................ 141
4.9.9 Anti-neoplastic properties....................................................................................................................................... 142
4.9.10 Emerging potential therapeutic uses ..................................................................................................................... 146
5.0 Precautions ........................................................................................................................................................................... 147
6.0 Warnings .............................................................................................................................................................................. 148
6.1 Tolerance, dependence, and withdrawal symptoms ......................................................................................................... 149
6.2 Drug interactions ............................................................................................................................................................. 149
6.3 Drug screening tests ......................................................................................................................................................... 151
7.0 Adverse effects ..................................................................................................................................................................... 152
7.1 Carcinogenesis and mutagenesis ..................................................................................................................................... 153
7.2 Respiratory tract .............................................................................................................................................................. 154
7.3 Immune system ................................................................................................................................................................ 156
7.4 Reproductive and endocrine systems ............................................................................................................................... 158
7.5 Cardiovascular system ..................................................................................................................................................... 162
7.6 Gastrointestinal system and liver ..................................................................................................................................... 163
7.6.1 Hyperemesis ........................................................................................................................................................... 163
7.6.2 Liver ....................................................................................................................................................................... 164
7.7 Central nervous system .................................................................................................................................................... 164
The salve works in like 2-3 days
Hmm, have to try that. I can see it working in a couple days. Will take awhile for it's completely gone.
I guess it depends on how bad it is. A friend used it and said it was better in 2 days to her surprise.
